Capricor (CAPR) news
Recent news
Capricor Therapeutics spikes higher, up 33%
Capricor Therapeutics (NASDAQ: CAPR) shares surged 33% on August 24, 2026, following the release of updated clinical trial data for its lead candidate, CAP-1002, in the treatment of Duchenne muscular dystrophy (DMD) [1]. The data, presented at a recent medical conference, showed improved functional…
AInvest Wire · 7d agoCapricor Therapeutics announces extension of PDUFA target action date as FDA continues review of DeramioCel BLA
Capricor Therapeutics (NASDAQ: CAPR) has announced that the U.S. Food and Drug Administration (FDA) has agreed to extend the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for deramiocel, an investigational cell therapy for the treatment of…
AInvest Wire · 7d agoKaos Capital: Demands an immediate meeting, board change, and capital-preservation plan at Capricor
AInvest Wire · Aug 21, 2026Kaos Capital: plans to nominate two independent director candidates at Capricor & to seek board-led M&A and strategic alternatives committee
AInvest Wire · Aug 21, 2026Capricor Therapeutics shares up 65% after FDA agrees to review new Duchenne drug data
Capricor Therapeutics (NASDAQ: CAPR) announced on July 11, 2025, that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Deramiocel, its lead cell therapy candidate for the treatment of…
AInvest Wire · Aug 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.